On this basis, our group and others have recently shown that both the specific silencing of hepatic GLS isoenzyme by using molecular approaches based on small interference RNA technology or its inhibition by using small chemical inhibitors can ameliorate steatohepatitis and fibrosis in pre-clinical mouse models of Fatty Liver Disease (19, 36). Here, GLS is linked to fatty liver disease.